| Literature DB >> 24672513 |
Karin Schwaiger1, Katrin S Harms1, Meike Bischoff1, Petra Preikschat2, Gabriele Mölle2, Ilse Bauer-Unkauf2, Solveig Lindorfer1, Sandra Thalhammer1, Johann Bauer1, Christina S Hölzel1.
Abstract
Enterococcus faecalis (n = 834) and Enterococcus faecium (n = 135) from blood and feces of hospitalized humans, from feces of outpatients and livestock and from food were screened for their susceptibility to a quaternary ammonium compound (didecyldimethylammoniumchloride, DDAC) and to 28 antibiotics by micro-/macrodilution. The maximum DDAC-MIC in our field study was 3.5 mg/l, but after adaptation in the laboratory, MIC values of 21.9 mg/l were observed. Strains for which DDAC had MICs > 1.4 mg/l ("non-wildtype," in total: 46 of 969 isolates/4.7%) were most often found in milk and dairy products (14.6%), while their prevalence in livestock was generally low (0-4%). Of human isolates, 2.9-6.8% had a "non-wildtype" phenotype. An association between reduced susceptibility to DDAC, high-level-aminoglycoside resistance and aminopenicillin resistance was seen in E. faecium (p < 0.05). No indications for a common source of non-wildtype strains were found by RAPD-PCR; however, several non-wildtype E. faecalis shared the same variant of the emeA-gene. In addition, bacteria (n = 42) of different genera were isolated from formic acid based boot bath disinfectant (20 ml of 55% formic acid/l). The MICs of this disinfectant exceeded the wildtype MICs up to 20-fold (staphylococci), but were still one to three orders of magnitude below the used concentration of the disinfectant (i. e., 1.1% formic acid). In conclusion, the bacterial susceptibility to disinfectants still seems to be high. Thus, the proper use of disinfectants in livestock surroundings along with a good hygiene praxis should still be highly encouraged. Hints to a link between antibiotic resistance and reduced susceptibility for disinfectants-as seen for E. faecium-should be substantiated in further studies and might be an additional reason to confine the use of antibiotics.Entities:
Keywords: QAC; aminoglycoside; antimicrobial resistance; antiseptic; biocide; disinfectant; enterococci; formic acid
Year: 2014 PMID: 24672513 PMCID: PMC3957061 DOI: 10.3389/fmicb.2014.00088
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Antibiotic agents, concentration ranges, and breakpoints.
| Amoxicillin/ Clavulanic acid | 1/2–128/2 0.125/2–8/2 | 8 4 | 8 8 | Gram-neg. Gram-pos. | EUCAST |
| Ampicillin | 1/2–128/2 0.125/2–8/2 | 8 4 | 8 8 | Gram-neg. Gram-pos. | EUCAST |
| Cefaclor | 1–8 | 1 | 4 | Gram-neg. | DIN1 |
| Cefazolin | 0.125–16 | 4 | 8 | Gram-neg. Gram-pos. | DIN |
| Cefoxitin | 2–16 | 4 | 8 | Gram-neg. | DIN |
| Cefuroxime | 0.5–64 1–8 | 8 4 | 8 8 | Gram-neg. Gram-pos. | EUCAST DIN |
| Chloramphenicol | 2–64 | 16 | 16 | Enterococci | DANMAP |
| Ciprofloxacin | 0.0625–8 0.25–32 | 0.5 1 | 1 2 | Gram-neg. Gram-pos. | EUCAST DIN |
| Clindamycin | 0.0625–8 | 1 | 4 | Gram-pos. | DIN |
| Doxycycline | 0.5–4 0.125–16 | 1 | 4 | Gram-neg. Gram-pos. | DIN |
| Enrofloxacin | 0.0625–8 | 0.25 | 2 | Gram-neg. Gram-pos. | CLSI |
| Erythromycin | 0.0625–8 | 1 | 4 | Gram-pos. | DIN |
| Florfenicol | 2–64 2–32 | 16 | 16 | Gram-neg. Gram-pos. | DIN |
| Fosfomycin | 8–64 | 32 | 32 | Gram-pos. | EUCAST |
| Gentamicin | 0.25–32 | 2 1 | 4 1 | Gram-neg. Gram-pos. | EUCAST EUCAST |
| Gentamicin HL | 512 | 512 | 512 | Enterococci | DANMAP |
| Imipenem | 0.125–16 | 2 4 | 8 8 | Gram-neg. Gram-pos. | EUCAST |
| Linezolid | 0.125–16 | 4 | 4 | Gram-pos. | EUCAST |
| Meropenem | 0.125–16 | 2 | 8 | Gram-neg. | EUCAST |
| Mezlocillin | 2–256 | 4 | 16 | Gram-pos. | DIN |
| Moxifloxacin | 0.0625–8 | 1 | 2 | Gram-pos. | DIN |
| Rifampicin | 0.5–4 | 0.006 | 0.5 | Gram-pos. | EUCAST |
| Streptomycin HL | 256–2048 | 512 | 512 | Enterococci | EUCAST |
| Synercid | 0.125–16 | 1 | 4 | Gram-pos. | EUCAST |
| Teicoplanin | 0.25–32 | 2 | 2 | Gram-pos. | EUCAST |
| Tobramycin | 0.25–32 | 2 | 4 | Gram-neg. | EUCAST |
| Tylosin | 0.5–4 | 4 | 4 | Gram-pos. | DANMAP |
| Vancomycin | 0.5–64 | 4 | 4 | Gram-pos. | EUCAST |
DIN: DIN 58940-4; DANMAP: all DANMAP 2004, except tylosin: DANMAP 1997 (.
Except E. faecalis.
For staphylococci.
High level concentrations indicative for aminoglycoside/penicillin synergism.
Prevalence of .
| Hospital: human blood | 6 (88) | 6.8 | 6 (62) | 0 (26) | 5 (60) | 1 (28) | 6 (85) | 0 (3) |
| Hospital: human feces | 8 (210) | 3.8 | 7 (144) | 1 (56) | 6 (177) | 2 (33) | 8 (210) | 0 (0) |
| Outpatient feces | 3 (102) | 2.9 | 3 (94) | 0 (8) | 3 (96) | 0 (16) | 3 (102) | 0 (0) |
| Swine, feces | 0 (76) | 0.0 | ||||||
| Cattle, feces | 0 (50) | 0.0 | ||||||
| Cattle, matistis milk | 0 (50) | 0.0 | ||||||
| Chicken, feces | 2 (50) | 4.0 | 2 (48) | 0 (2) | 2 (46) | 0 (4) | 2 (50) | 0 (0) |
| Milk and dairy products | 14 (96) | 14.6 | 13 (95) | 14 (95) | 0 (1) | 2 (96) | 0 (0) | |
| Poultry | 2 (54) | 3.7 | 2 (54) | 0 (0) | 2 (43) | 0 (11) | 2 (54) | 0 (0) |
| Beef | 3 (30) | 10.0 | 3 (30) | 0 (0) | 3 (29) | 0 (1) | 3 (30) | 0 (0) |
| Pork | 1 (28) | 3.6 | 1 (26) | 0 (2) | 1 (25) | 0 (3) | 1 (28) | 0 (0) |
| Hospital: human blood | 3 (45) | 6.7 | 1 (31) | 2 (14) | 1 (32) | 2 (13) | 0 (7) | 3 (38) |
| Hospital: human feces | 2 (52) | 3.8 | 0 (42) | 0 (43) | 0 (38) | |||
| Outpatient: feces | 2 (38) | 5.3 | 2 (38) | 0 (0) | 2 (36) | 0 (2) | 2 (37) | 0 (1) |
GNH gentamicin (high level).
SNH streptomycin high level.
AMP ampicillin.
Differs significantly in a Fisher's Exact Test from the overall prevalence in this study, .
Bold: emphasized for the sake of clarity
Minimal inhibitory concentrations and antimicrobial resistance of antiseptic-tolerant (MIC > 1.4 mg DDAC/l) .
| Hospital: Human blood | 1 | 2.1 | 1 | – | CIP ENR LEV MOX DOX ERY TLS TEL SNH | |
| 1 | 2.1 | 2 | – | DOX ERY | ||
| 1 | 2.45–3.5 | n.d. | qacA/B+ | DOX ERY | ||
| 1.75 | 2 | qacA/B− | DOX ERY | |||
| 1 | 1.05–>1.4 | 1 | – | DOX | ||
| 2 | 2.1 | 0 | – | – | ||
| Human feces | 1 | 1.75 | 0 | – | CIP ENR LEV MOX ERY TLS TEL GNH SNH | |
| 1 | 2.45–3.5 | n.d. | – | DOX ERY SNH | ||
| 1 | 1.75 | 2 | – | DOX ERY TLS | ||
| 1 | 1.75 | 1 | – | DOX ERY | ||
| 1 | 2.1 | 0 | – | DOX | ||
| 1 | 1.75 | 0 | – | – | ||
| 1 | 2.8–3.5 | 2 | – | – | ||
| 1 | 3.5 | 1 | – | – | ||
| Outpatients: Human feces | 1 | 2.1 | 2 | – | DOX ERY | |
| 1 | 2.1–2.45 | 2 | – | – | ||
| 1 | 2.45–3.5 | 2 | – | |||
| Animal: Chicken | 2 | 1.05–1.75 | 1/0 | – | – | |
| Milk and dairy products | 1 | 1.75 | 1 | – | ERY TLS TEL GNH | |
| 2 | 2.1 | 0 2 | – | ERY | ||
| 3 | 1.75 | n.d. /1 | – | – | ||
| 1 | 1.75–2.1 | /0 | – | |||
| 1 | 2.1 | x | ||||
| 5 | 2.1–2.45 | x/1/2/0/0 | – | |||
| 1 | 2.1–3.5 | 2 | – | |||
| 1 | 2 | – | ||||
| Meat: Poultry | 1 | 1.05–>1.4 | 0 | – | – | |
| 1 | 2.1 | 1 | – | |||
| Beef | 1 | 1.75 | 0 | – | ERY | |
| 1 | 1.75 | 2 | – | – | ||
| 1 | 2.1 | 2 | – | – | ||
| Pork | 1 | 2.1 | 2 | – | ERY | |
| Hospital: Human blood | 1 | 1.75 | n.d. | – | AMC AMP MZL IMP MER CIP ENR LEV MOX ERY TLS TEL GNH | |
| 1 | 1.75 | n.d. | – | AMC AMP MZL IMP MER CIP ENR LEV MOX ERY TLS TEL SNH | ||
| 1 | 1.75 | n.d. | – | AMC AMP MZL IMP MER CIP ENR LEV MOX ERY TLS TEL SNH GNH | ||
| Human feces | 1 | 1.75 | n.d. | – | AMC AMP MZL IMP MER CIP ENR LEV MOX ERY TLS TEL SNH GNH | |
| 1 | 1.75 | n.d. | – | AMC AMP MZL IMP MER CIP ENR LEV MOX ERY TLS TEL SNH GNH | ||
| Outpatients: Human feces | 1 | 1.05–>1.4 | n.d. | – | ERY TLS LIZ | |
| Healthy humans: | ||||||
| 1 | 1.4–>1.4 | n.d. | – | CIP ENR ERY | ||
| 1 | 2.8 | n.d. | n.d. | CIP ENR DOX GNH |
(Bischoff et al., .
Originating from different patients of the same hospital in the same period of investigation, respectively;
isolates of two different outpatients, sent in from the same laboratory in the same period of investigation.
DDAC, Didecyldimethylammoniumchloride; AMC, Amoxicillin + Clavulanate; AMP, Ampicillin; MZL, Mezlocillin; IMP, Imipenem; MER, Meropenem; CIP, Ciprofloxacin; ENR, Enrofloxacin; LEV, Levofloxacin; MOX, Moxifloxacin; ERY, Erythromycin; TLS, Tylosin; TEL, Telithromycin; GNH, Gentamicin High Level; SNH, Streptomycin High Level; LIZ, Linezolid.
Investigated qac-genes: qacA/B, qacC, qacD, qacEΔ1, qacG, qacH/qacZ, qacJ.
DDAC-tolerance was reproduced twice, but not at the third time.
Figure 1MIC-values (log2) of didecyldimethylammoniumchloride (DDAC) in .
Figure 2Amplicon-typing (RAPD-PCR) of .
Figure 3Amplicon-typing (RAPD-PCR, two different conditions) of .
Figure 4Conventional melting curve analysis (Lightcycler I.I, SYBR-Green) of .
Polymorphism analysis (NCBI BLAST) of .
| Goulash (pork) | 2.0 | 1 | _141G_251 |
| Whipped cream | 2.2 | 1 | Sequence as above |
| Child (gastro-intestinal disorder) | 2.7 | 1 | Sequence as above |
| DSMZ (urine) | 1.05 | 2 | _141G_251A_305G_311C_320G_392T_402G_407G G_491T_551A_560T_563a_572g_779C_855C__431C_479 |
Bold letters: differ from DSM 2570. Other letters: identical with DSM 2570 but variable in other E. faecalis-emeA-entries in the Genbank database. _ spacer for conserved regions in all genbank entries.
Unique variant not seen in any other genbank-entry.
Antimicrobial resistance and susceptibility to disinfectants of bacteria isolated from boot bath disinfectant (2% concentrate = 1.1% formic acid).
| 0.006 | 0.001 | CIP FOS | CEC | |
| 0.003 | 0.008 | CLI ERY ROX TYL DOX | MZL MER | |
| 0.07 | 0.004 | TYL | – | |
| 0.14 | 0.008 | – | GN | |
| 0.14 | 0.008 | DOX | GN | |
| 0.14 | 0.008 | CEC | GN | |
| 0.14 | 0.008 | DOX CEC | GN | |
| 0.14 | 0.008 | AMC | GN | |
| 0.14 | 0.008 | – | GN | |
| 0.14 | 0.008 | – | GN + AMC CEC CEZ COX CXM | |
| n.d. | >0.01 | CEC DOX ENR FOS | ||
| n.d. | n.d. | n.d. | n.d. | |
| n.d. | n.d. | GN + AMC CEC CEZ CXM CIP | ||
| 0.14 | 0.03 | FOS | GN + AMC CEC COX CEZ CXM | |
| n.d. | >0.01 | – | GN | |
| 0.14 | 0.008 | – | GN + AMC CEC CEZ COX CXM | |
| n.d. | >0.01 | CEZ FOS | GN | |
| 0.06 | 0.002 | FOS | GN + AMC CEC CEZ COX CXM | |
| 0.14 | 0.03 | AMC CEC CEZ FOS DOX TOB | GN | |
| 0.14 | 0.03 | FOS DOX TOB | GN | |
| n.d. | >0.01 | – | GN + AMC CEC CEZ COX CXM | |
| 0.003 | 0.001 | – | AMC CEC CEZ COX CXM OXA PEN | |
| 0.01 | 0.002–0.03 | CLI ERY TEL FOS | CXM OXA PEN | |
| n.d. | >0.01 | – | FOS | |
| 0.006 | 0.001 | – | FOS CLI | |
| 0.003 | 0.001 | – | – | |
| 0.003 | 0.008 | n.d. | n.d. | |
| 0.02 | 0.008 | CLI | ERT FOS MER MOX | |
| 0.01 | 0.008 | ERY TLS | CLI SYN | |
| 0.003 | 0.008 | – | – | |
No growth in TS-broth, CAMHB, and Wilkens Chalgren broth in aerobic or anaerobic conditions.
GN: natural resistance to antibiotics which are ineffective in Gram-negatives like benzylpenicillin, macrolides, lincosamides, streptogramins. DDAC, Didecyldimethylammoniumchloride; AMC, Amoxicillin + clavulanate; AMP, Ampicillin; CEC, Cefaclor; CEZ, Cefazolin; CIP, Ciprofloxacin; COX, Cefoxitin; CXM, Cefuroxime; FOS, Fosfomycin; DOX, Doxycycline; MER, Meropenem; ENR, Enrofloxacin; ERT, Ertapenem; ERY, Erythromycin; LEV, Levofloxacin; MOX, Moxifloxacin; TLS, Tylosin; TEL, Telithromycin.